FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

	9.0,	 	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
011011	2005 2005							
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

												' '								
1. Name and Address of Reporting Person*  ABERCROMBIE GEORGE B					BI	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC									eck all app	licable)				
						BCRX ]											Director Officer (give title below)		Other (	· I
(Last) (First) (Middle) PO BOX 16069						3. Date of Earliest Transaction (Month/Day/Year) 04/18/2022													below)	specify
		4 11	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable											nlicable						
(Street)						4. If Afficiation of John Group Filling (Check Applicate Line)											, poubo			
CHAPEL HILL NC 27516																X Form filed by One Reporting Person				
																Form filed by More than One Reporting Person				
(City)	(	State)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution Date,		, Transaction Dispose Code (Instr. 5)		Dispose	rities Acquired (A) o ed Of (D) (Instr. 3, 4 a			Securi Benef Owner	cially I Following	es Form ally (D) of Following (I) (II		7. Nature of Indirect Beneficial Ownership		
										Code	v	Amount		(A) or (D)	Price	Repor Transa (Instr.	ted action(s) 3 and 4)			(Instr. 4)
Common Stock <sup>(1)</sup> 04/18/2					3/2022				M		5,000		A	\$3.3	5,000			D		
Common Stock <sup>(1)</sup> 04/18/2					3/2022	2022			S		5,000 D		\$11.0	)4	0		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deem Execution if any (Month/Da	Date,	ate, Transac		of		Ex	6. Date Exercisa Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price o Derivative Security (Instr. 5)		e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Da Ex	te ercisable		xpiration ate	Title	1	Amount or Number of Shares					
Automatic Stock Option Grant <sup>(1)</sup>	\$3.32	04/18/2022			М			5,000		(2)	0:	5/23/2022	Com Sto		5,000	\$0	0		D	

## **Explanation of Responses:**

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.
- 2. The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.

/s/ Alane P. Barnes, by power 04/20/2022 of attorney

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.